DiaMedica Therapeutics (NASDAQ:DMAC) Rating Increased to Sell at Wall Street Zen

DiaMedica Therapeutics (NASDAQ:DMAC) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Stock Performance

NASDAQ:DMAC opened at $5.64 on Friday. The stock has a fifty day moving average price of $6.25 and a 200-day moving average price of $7.48. The company has a market cap of $303.88 million, a price-to-earnings ratio of -7.94 and a beta of 0.97. DiaMedica Therapeutics has a fifty-two week low of $3.47 and a fifty-two week high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Research analysts predict that DiaMedica Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Cooperman Leon G increased its stake in shares of DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after buying an additional 1,619,761 shares during the period. Millennium Management LLC acquired a new stake in shares of DiaMedica Therapeutics in the third quarter valued at about $8,157,000. Paragon Associates & Paragon Associates II Joint Venture increased its stake in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after buying an additional 225,000 shares during the period. Geode Capital Management LLC increased its stake in shares of DiaMedica Therapeutics by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after buying an additional 52,437 shares during the period. Finally, State Street Corp increased its stake in shares of DiaMedica Therapeutics by 31.7% in the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock valued at $4,997,000 after buying an additional 151,188 shares during the period. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.